Wuxi Biologics Placement - Smaller Deal than Previous as Last Didn’t Do Well, Overhang Remain
Wuxi Biologics Holdings is looking to raise up to US$288m by selling about 2% of Wuxi Biologics (2269 HK). This will be the 17th placement in the...
710 Views
Keymed Bioscience Placement - Track Record Isn’t Great but Recent Performance Has Been Better
Keymed Biosciences (2162 HK), along with its controlling shareholder, is looking to raise around US$112m to fund its R&D requirements.
418 Views
Xtalpi US$860m IPO Lockup Expiry - Last of the Lockup Release with Nearly All Shares in CCASS Now
XtalPi Holdings (2228 HK) was listed in Hong Kong on 13th Jun 2024 after raising US$126m. Its one-year lockup will expire soon.
751 Views
Pre-IPO Medtide (PHIP Updates) - Some Points Worth the Attention
​GLP-1 sales growth is at a turning point with market size potentially lower than expected, impacting growth outlook for peptide CXOs like Medtide....
389 Views
A-H Premium Weekly (Jun 6th): Jiangsu Expressway, Sichuan Expressway, CICC
We analyzed A-H premium changes in the past week and highlight A-H premium changes for Jl Mag Rare-Earth, Jiangsu Expressway, Sichuan Expressway,...
380 Views